Tonix Reports 2,145 Prescribers, 5,400 Q1 Prescriptions; Secures 35M-Lives GPO Deal
TNXP•Tonix reported 2,145 providers prescribing TONMYA, 3,588 patient starts and 5,400 filled prescriptions in Q1 and held $185.5 million cash at quarter-end. It secured a managed care deal covering 35 million commercial lives and plans Phase 2 Lyme prevention study in H1 2027 and a Phase 2 MDD trial mid-2026.
1. Q1 Sales and Commercial Uptake
Tonix recorded 2,145 unique healthcare providers prescribing TONMYA in Q1, with 3,588 patients initiating therapy and approximately 5,400 prescriptions filled, including bridge prescriptions. Repeat prescriber and patient refill trends were encouraging through the first full quarter since launch in November 2025.
2. Managed Care and Market Access Expansion
In May, the company secured a managed care agreement with a leading GPO covering access to TONMYA for about 35 million U.S. commercial lives. TONMYA is also covered under Medicaid in 38 states, representing 73% of 75 million Medicaid lives, supported by patient savings cards and prior authorization assistance.
3. Financial Position
Tonix held $185.5 million in cash and cash equivalents as of March 31, 2026, providing runway for ongoing commercial launch activities and development programs.
4. Pipeline Development and Upcoming Trials
The company plans to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in H1 2027, pending FDA agreement, with a Type C meeting scheduled for early Q3 2026. A Phase 2 study of TONMYA for major depressive disorder is expected to begin mid-2026, alongside other CNS and immunology programs.
